Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plamotamab - Xencor

Next Previous
Drug Profile

Plamotamab - Xencor

Alternative Names: CD20 x CD3; XmAb 13676

Latest Information Update: 12 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Rheumatoid arthritis
  • Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Nov 2025 Phase-I/II clinical trials in Rheumatoid arthritis (Treatment-experienced) (Parenteral)
  • 21 Oct 2025 Phase-I clinical trials in Rheumatoid arthritis in New Zealand, Moldova, Georgia (SC) (NCT07230353)
  • 01 Jun 2025 Xencor receives regulatory authorisation for phase Ib/IIa trial for Plamotamab in Rheumatoid arthritis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top